Kornimate/medical-research-clean huggingface dataset:
narrow-band uvb-therapy in psoriasis

Conditions: Psoriasis

Summary: study on two different irradiation schemes in uvb phototherapy for psoriasis. previous studies demonstrated a similar clinical effect in erythematogenic and suberythematogenic irradiation, with less complications in suberythematogenic irradiation. most of these studies used both irradiation schemes within the same patient. uvb has a systemic effect on the body. our hypothesis is that previous conclusions are incorrect and that the erythematogenic scheme will result in earlier clearance of the psoriasis.

109 psoriasis patients, referred for uvb phototherapy, participated in our study after given their written informed consent. after determining the minimal erythema dose (med) patients were randomised in either group 1, erythematogenic scheme, or group 2, suberythematogenic scheme. group 1 started with 70% of med and every following irradiation with an increase of 40%. group 2 started with 30% of med and every next visit an increase of 20%. the study protocol was adjusted in case of erythema (sunburn) according to a standard erythema-phototherapy protocol, varying from skip one irradiation to lowering the percentage of increase. in case of clearance the study stopped. clearance was defined as less than 10% of baseline body area of psoriasis.

Eligibility criteria:
inclusion criteria: * eligible for uvb phototherapy * older than 18 years exclusion criteria: * no topical medication for 2 weeks * no systemic medication for 4 weeks * no medication (betablocker, lithium) interfering with psoriasis
cytoprotective effect and clinical outcome of perioperative proesterone in brain tumors

Conditions: Diffuse Traumatic Cerebral Edema

Summary: neuronal injury is evident in elective craniotomy for space occupying lesions. surgical trauma and mechanichal impact of the tumor causes neuronal injury. neurosreroid progesterone is a neurotransmittern , trail to use in abolishing neurotoxcicty

progesterone is a natural neurosteroid that we are trying to use to impede both direct neuronal injury cauesd by and indirectly by surgical trauma. progesterone can decreas vasogenic brain oedema. our primary outcome is to ameliorate microscopic cytoplasmic injury and decrease brain oedema exploited by biopsy from brain tumor interface. exclusion criteria demonstratd as refusal to participate in the trial , emergency craniotomy, recurrent brain tumor.

Eligibility criteria:
inclusion criteria: * all elective brain tumors elligible for craniotomy exclusion criteria: * refusal to participare * emergency craniotomy

Keywords: progesterone brain tumor neuronal biopsy
determination of exercise behavior in patients with juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis

Summary: juvenile idiopathic arthritis (jia) is one of the most common rheumatic diseases in childhood, affecting at least 1 in 1000 children. children with jia experience joint inflammation and swelling, pain and tenderness, morning stiffness, limited mobility. children with jia complain pain and have lower functional ability and decreased quality of life compared with their peers. many studies have reported that patients with jia have low physical activity levels and also exercise therapy is considered an important component of the treatment of jia. nowadays, studies for evaluating exercise behaviours in order to cope with physical inactivity for many chronic diseases are becoming increasingly important.the objective of this study is to determine exercise behaviour in patients with jia.


Eligibility criteria:
inclusion criteria: * diagnosed as jia according to ilar classification * aged between 6-18 * adequate cognitive function for understanding questions exclusion criteria: - a parent who does not have a smartphone

Keywords: juvenile idiopathic arthritis exercise behavior
prevention of alcohol intolerance

Conditions: Alcohol Sensitivity

Summary: this study is designed to determine whether asians who are especially sensitive to alcohol exposure can be protected by boosting their activities of an alcohol disposing enzyme. this will be accomplished by administering broccoli sprouts that are rich in an agent that increases protective enzyme activity. the test system involves applying alcohol patches to the skin and measuring skin redness.


Eligibility criteria:
inclusion criteria: * 18-70 years old, * sensitive to alcohol on the skin, japanese exclusion criteria: * recent skin abnormalities /tanning

Keywords: broccoli sprouts alcohol sensitivity sulforaphane alcohol metabolism in the asian community
the role of angiotensinogen gene polymorphism in the pathogenesis of non-familial sick sinus syndrome

Conditions: Sick Sinus Syndrome

Summary: evidence has been documented for the close relationship between the arrhythmia pathogenesis and the gene expression in renin-angiotensin system. however, it remains unclear for involvement of ras in the pathogenesis of non-familial sick sinus syndrome. the researchers thus investigated the possible relationship between non-familial sick sinus syndrome and the polymorphism and haplotype of the agt promoter.


Eligibility criteria:
inclusion criteria: * sick sinus syndrome exclusion criteria: * 1.severe systemic disease. * 2.acute coronary syndrome. * 3.bradycardia with reversible cause.
medical nutrition formulations enriched with postbiotics for the management of gastrointestinal disorders

Conditions: Diarrhoea of Diverse Aetiology Requiring Oral Rehydration Therapy; Diarrhoea and Gastrointestinal Symptoms Secondary to Enteral Nutrition

Summary: efficacy and tolerability of abb i5 prebiotic and abb c22 postbiotics for the management of constipation and gastrointestinal well-being: a pilot trial


Eligibility criteria:
inclusion criteria: * inpatients of the centre * diagnostic of diarrhoea: increase in daily faecal weight \> 200 g (as per the centre protocol). * subjects who as per the centre protocol require oral rehydration therapy * patients with the ability to take the study product orally exclusion criteria: * history of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active principle or to any of the excipients. * history or evidence of any medical conditions or medication used that, in the opinion of the principal investigator, could affect the safety of the subjects or interfere with the study evaluations * patients in situation of last days * amytriptilin and masalazine treatment (anti-depressives) * laxatives

Keywords: diarrhoea postbiotic adults
the effects of strawberries on blood cholesterol.

Conditions: Hyper-LDL-cholesterolemia; Metabolic Syndrome

Summary: in this study, we propose to investigate the effects of dietary achievable doses of strawberries on serum ldl-cholesterol (ldl-c) and related lipid profiles, measures of glycemia and insulin resistance, and biomarkers of inflammation in a 14 week controlled crossover study.

the screen visit will involve an 8 hour fasting state and the following procedures: * completing screening questionnaire * measuring height, weight, blood pressure, and waist size * drawing about 30ml blood for blood glucose and lipids and comprehensive metabolic panel all subjects will be asked to follow usual diet and lifestyle, and refrain from other sources of berries and related products while on the study. subjects will also maintain 3-day food records at screen, 4, 9, and 14 weeks of the study. height, weight, blood pressure and waist circumference will be measured by trained personnel at mpe 326 (kns facility for clinical research). blood draws will be performed by trained phlebotomists (to be hired) at mpe 326, and all procedures will be performed by trained research personnel \[pi \&co-pi: basu, izuora and graduate student\]. in case of blood pressure, an average of at least three readings, 10 min apart, will be measured at each visit for each participant. blood glucose (fasting and postprandial at two hours) will be determined at each time point. the oral glucose tolerance tests will be conducted at mpe 326 and blood samples will be sent to quest diagnostics, las vegas. insulin resistance will be calculated using the homoeostatic model assessment (homa-ir). the homa-ir is a standard and widely used formula in calculating insulin resistance based on fasting glucose values. screening and follow-up tests will include clinical laboratory tests for blood glucose, lipids, nmr profiles, c-reactive protein and metabolic panel to determine effects of the intervention.

Eligibility criteria:
inclusion criteria: * elevated total and ldl cholesterol (\>116 mg/dl) * body mass index (\> or = 30 kg/m2) * features of the metabolic syndrome exclusion criteria: * taking glucose and lipid lowering medications (e.g. statins, metformin) * history of chronic conditions (diabetes, chd, anemia, renal diseases) * allergic to strawberries * pregnant and/or lactating * smoking * vegetarian or consuming special diet
phase 2 study of gemcitabine or gemcitabine + enzastaurin in participants with advanced or metastatic pancreatic cancer

Conditions: Pancreatic Neoplasm

Summary: the purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.


Eligibility criteria:
inclusion criteria: * diagnosis of adenocarcinoma of the pancreas. * pretreatment tumor specimen must be available. * no prior chemotherapy immunotherapy, biological therapy, or hormonal therapy for pancreatic cancer, including 5-fluorouracil (5-fu) with radiation therapy. * prior radiation allowed. * ability to stop some types of anti-seizure medicines within 14 days of enrollment. exclusion criteria: * endocrine pancreatic tumor or ampullary cancer. * central nervous system (cns) metastases. * inability to swallow tablets. * 10% or greater weight loss over the 6 weeks before study entry.
different sutures in hand surgery

Conditions: All Minor Hand Surgery Including; Carpal Tunnel Syndrome; Trigger Finger; Ganglion Cysts; De Quervain Syndrome; Dupuytren Contracture

Summary: this study aims to assess the relationship between overall satisfaction with treatment in a group of randomized patients undergoing elective hand surgery using either absorbable (4-0 chromic) or non-absorbable (5-0 nylon) sutures. the investigators will also assess factors associated with wound concerns, pain intensity, magnitude of limitations, and physical function within one month of surgery.


Eligibility criteria:
inclusion criteria: * all patients undergoing common day-case elective hand surgery under local anesthesia, one of the following (initial) procedures: * carpal tunnel release * trigger finger release * ganglion excision * excisional biopsy * de quervain release * dupuytren fasciectomy * any other minor hand surgery * patients aged 18-89 * able to provide informed consent * able to understand english or spanish to complete questionnaires * patients who have an email-address or phone number (needed for follow-up) * ut health austin musculoskeletal institute, austin regional clinic, orthopaedic specialists of austin. * available for follow-up contact after 4 weeks exclusion criteria: * patients not able to give informed consent * patients using corticosteroids * patients with one of the following comorbidities: bleeding disorder, immunodeficiency, collagen vascular disease. * patients known to be allergic to suture materials * revision procedures
the effect of mydriatic eye drops on cerebral and mesenteric oxygenation in preterm infants

Conditions: Prematurity of Fetus

Summary: near infrared spectroscopy offers the possibility of noninvasive and continuous bedside investigation of cerebral and mesenteric oxygenation in newborn infants. using this technique the investigators investigated the effect of mydriatic eye drops on cerebral and mesenteric oxygenation in preterm infants

the cerebral and mesenteric oxygenation will be measured by nirs before, during and after the mydriatic eye drops are instilled.

Eligibility criteria:
inclusion criteria: 1. \< 32 gestational age and/or \< 1500gr. 2. ≥ 28th day preterm infants 3. instilled mydriatic eye drops for rop examination exclusion criteria: 1. sepsis 2. shock 3. severe intracranial hemorrhage 4. nec 5. abdominal and cranial surgery

Keywords: mydriatic nirs preterm eye drops cerebral mesenteric oxygenation
compare safety and efficacy of bibf 1120 versus sunitinib.

Conditions: Carcinoma, Renal Cell

Summary: compare safety and efficacy of bibf 1120 versus sunitinib in patients with advanced rcc and to investigate the effects of bibf 1120 on the heart rate (hr) corrected qt interval (qtcf).


Eligibility criteria:
inclusion criteria: 1. patients with unresectable or metastatic renal cell cancer, who have received no previous systemic anti-cancer treatment. 2. histological-confirmed diagnosis of renal cell cancer with clear cell component. 3. acceptable renal,liver,cardiovascular,bone marrow and other functions to allow sunitinib/bibf 1120 treatment. exclusion criteria: 1. patients unable to tolerate sunitinib/bibf 1120 treatment 2. treatment with other investigational drugs or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study. 3. patients unable to comply with the 1199.26 protocol. 4. pregnancy or breast feeding. 5. active alcohol or drug abuse. 6. women of child bearing potential, or men who are able to father a child, unwilling to use a medically acceptable form of contraception during the study period.
a multicentre study in otherwise healthy infants and toddlers hospitalised for and diagnosed with rsv lower respiratory tract infection to evaluate the safety, tolerability, and clinical activity of alx-0171

Conditions: Respiratory Syncytial Virus Infection

Summary: the primary objective of the study is to investigate the safety and tolerability of alx-0171. the secondary objectives are to evaluate the clinical effect of alx-0171 and to explore the pharmacodynamics (pd) and the systemic pharmacokinetics (pk) of alx-0171.


Eligibility criteria:
inclusion criteria: 1. subject is otherwise healthy, but hospitalised for and clinically diagnosed with rsv lrti (lower respiratory tract infection) 2. subject has appearance of upper or lower respiratory tract infection symptoms that are likely related to rsv 3. subject has a positive rsv diagnostic test 4. others as defined in the protocol exclusion criteria: 1. subject has history of wheezing 2. subject is known to have significant comorbidities 3. subject is known to be immunocompromised 4. subject is suspected of having a clinically relevant infection other than rsv 5. others as defined in the protocol
bilateral bispectral index (bis) study

Conditions: Cerebral Vasospasm; Delayed Cerebral Ischemia; Subarachnoid Hemorrhage

Summary: the purpose of this study is to assess real time changes in raw and processed eeg in relation to the clinical and radiological evidence of cerebral vasospasm.

subarachnoid hemorrhage (sah) is a prevalent and morbid condition (45%-30 day mortality). one of the major causes of reduced cerebral blood flow (cbf) after initial sah is cerebral vasospasm. early treatment of cerebral vasospasm (\< 2 hr) is necessary for improved neurologic outcome. hence, there is significant interest in development of a monitor. the most common bedside diagnostic tool is transcranial doppler (tcd) which is controversial given its low sensitivity and specificity. tcd is not a continuous monitor and is user dependent. many centers rely on cerebral angiography for diagnosis of vasospasm; however angiographic spasm does not correlate with outcome. eeg can detect changes in cerebral blood flow which precede clinical decline but is technically difficult to perform and not practical for continuous monitoring. processed eeg monitors have become somewhat popular in the operating setting for assessment of depth of anesthesia. the recent introduction of bilateral 4 channel disposable probes presents to opportunity to use eeg as a non-invasive continuous monitor for vasospasm. we propose a prospective observational study to assess real time changes in raw and processed eeg which we will correlate with clinical and radiologic evidence of vasospasm. our primary clinical endpoint will be the determination of delayed cerebral ischemia. this modality could prove to be a significant clinical advantage for patients suffering from sah.

Eligibility criteria:
inclusion criteria: * adult men or women of any age and ethnicity within 48 hours of subarachnoid hemorrhage (sah) exclusion criteria: * age \< 18 years * greater than 48 hours past the initial hemorrhage * previous history of stroke of any etiology * inability to consent for themselves or have a proxy to consent for them (implied consent)

Keywords: cerebral vasospasm delayed cerebral ischemia (dci) subarachnoid hemorrhage (sah) patients
allogeneic bone marrow mesenchymal stem cells for patients with interstitial lung disease (ild) & connective tissue disorders (ctd)

Conditions: Interstitial Lung Disease; Connective Tissue Diseases

Summary: researchers are trying to find out more about the safety of a new treatment, allogeneic (coming from a healthy donor) bone marrow derived mesenchymal stem cells (bmd-mscs) which is still experimental, for interstitial lung disease (ild) associated with connective tissue disorder (ctd).


Eligibility criteria:
inclusion criteria: * adults over 18 years of age and less than 80 years of age * both female and male * patients with new diagnosis of interstitial lung disease associated with connective tissue disorders, antineutrophil cytoplasmic antibodies (anca) associated vasculitis or idiopathic pneumonia with autoimmune features (ipaf) or established diagnosis of ild associated with ctd under conventional therapy for at least 6 months but less than 24 months, with no evidence of improvement. * competent and able to provide written informed consent, and ability to comply with protocol exclusion criteria: * patients with interstitial lung disease without evidence of a concomitant rheumatologic autoimmune disorder * exposure to rituximab or cyclophosphamide on the previous 2 months * severe interstitial lung disease defined by the presence of severe hypoxemia at rest (so2 \< 88% at rest) * clinical assessment that indicates active chronic infections such as osteomyelitis or active tuberculosis (tb), or acute infections such as pneumonia, active bronchitis, cellulitis, etc. or active solid tumors or hematologic malignancies * previous treatment with mesenchymal stem cells * clinically significant medical conditions within the six months before administration of bmd-mscs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient. * medical history of human immunodeficiency virus (hiv), hepatitis b or c * abnormal complete blood count (cbc), creatinine, aspartate aminotransferase (ast) or alanine aminotransferase (alt) at screening * pregnant or breast feeding * unwilling to agree to use acceptable contraception methods during participation in the trial * inability to provide informed consent
a novel transition program to reduce disability after stroke

Conditions: Ischemic Stroke; Hemorrhagic Stroke

Summary: this study evaluates a program designed to help individuals transition home from inpatient rehabilitation following an ischemic or hemorrhagic stroke. half of the participants will receive a stroke education program while the other half will receive an environmental modifications program.

a gap in care exists at the point of transition from inpatient rehabilitation (ir) to home, when survivors encounter new environmental barriers due to the cognitive and sensorimotor sequelae of stroke. resolving these barriers and improving independence in the community have potential to significantly improve stroke survivors' long-term morbidity. the proposed study investigates the efficacy and safety of a novel enhanced rehabilitation-transition program to reduce environmental barriers and improve daily activity performance and community participation.

Eligibility criteria:
inclusion criteria: * aged ≥50 years * acute ischemic or hemorrhagic stroke diagnosis * independent adls prior to stroke (premorbid modified rankin scale score ≤2) * plan to discharge to home exclusion criteria: * severe terminal systemic disease that limits life expectancy to \< 6 months * previous disorder (e.g. dementia) that makes interpretation of the self-rated scales difficult or short blessed test (sbt) score of 10 or less (indicating significant cognitive impairment) * moderate to severe aphasia as determined by the nihss best language rating of 2 or more * reside in congregate living facility.

Keywords: environmental modifications activity performance
pharmacokinetics (pk) study of a fluconazole loading dose in infants and toddlers

Conditions: Candidiasis

Summary: the purpose of this study is to investigate the pharmacokinetics and safety of a fluconazole loading dose in infants and toddlers.

this is an open label study to investigative the pharmacokinetics and safety of a fluconazole loading dose in infants and toddlers \ 48 hours and \ 30 weeks ega infants \> 48 hours and \< 31 days; infants ≥ 31 days and \< 2 years of age. the study requires administration of fluconazole over 1-5 days depending on treatment group followed by 1 week of safety monitoring. six to eight 100 µl pk samples will be obtained over the 5 days of drug administration. the risks are reasonable vs. the benefits and have been minimized appropriately. there may be benefit to the subjects (administration of empirical antifungal therapy), and information from the study may benefit a large number of other infants and toddlers with suspected or proven fungal sepsis. there is a data analysis plan.

Eligibility criteria:
inclusion criteria: * suspected sepsis with blood culture within 48 hours * age ≥ 48 hours and \< 2 years of age * sufficient venous access to permit study drug administration exclusion criteria: * allergic reaction to azole * history of fluconazole administration in prior 5 days * liver dysfunction * renal failure * concomitant use of cyclosporine, tacrolimus, or azithromycin

Keywords: fluconazole pharmacokinetic candidiasis sepsis pediatric infants antifungal candidemia fungemia loading dose
an open-label extension of a phase 3 study of otx-101 in the treatment of keratoconjunctivitis sicca

Conditions: Keratoconjunctivitis Sicca

Summary: this is a safety extension enrolling subjects participating in study otx-101-2016-001 (nct02688556)


Eligibility criteria:
inclusion criteria: * completion of study otx-101-2016-001 exclusion criteria: -